Unlocking the Mysteries of the Mind: Advancing Central Nervous System Research and Therapies
Geistek Pharmaceuticals is at the forefront of revolutionary advancements in cell and gene therapies, unlocking the potential to transform the landscape of healthcare. We are dedicated to developing innovative treatments that harness the power of cells and genes to provide hope and healing for patients with complex diseases.
Cell and gene therapies hold immense promise in addressing conditions that were once considered incurable. At Geistek Pharmaceuticals, we specialize in a wide range of therapeutic areas, leveraging cutting-edge technologies to develop personalized and targeted treatments. Our expertise spans diverse applications, including genetic disorders, oncology, neurodegenerative diseases, autoimmune disorders, and more.
Our passionate team of scientists, researchers, and medical professionals is committed to pushing the boundaries of scientific discovery. With a deep understanding of cellular biology, genetics, and immunology, we strive to develop therapies that restore health at the cellular level, addressing the underlying causes of disease.
Geistek Pharmaceuticals embraces a collaborative approach, working closely with leading academic institutions, clinical experts, and regulatory authorities to ensure the highest standards of safety and efficacy. We adhere to rigorous scientific protocols and follow stringent regulatory guidelines to advance the field of cell and gene therapies responsibly.
Through our comprehensive research and development efforts, we aim to provide patients with transformative treatments that have the potential to significantly improve their quality of life. We are driven by a shared vision of a future where cell and gene therapies are accessible and affordable, offering hope to individuals and families affected by challenging medical conditions.
Geistek Pharmaceuticals is committed to leading the way in cell and gene therapy innovation. We combine scientific expertise, cutting-edge technologies, and a patient-centered approach to bring life-changing therapies from the lab to the clinic. Together, let’s shape the future of healthcare through the power of cell and gene therapies.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
